WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.Presented ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...